Pfizer is maintained as a Buy due to its diversified and growing product portfolio, offering a 16% upside and about 7% dividend yield. The company is balancing losses from expiring patents and reduced COVID-19 sales with new growth products, cost controls, and business restructuring, which supports stable future earnings. Pfizer's upcoming Q2 earnings report is expected to surpass conservative forecasts, with management updates on its drug pipeline and new product launches seen as key growth drivers. Risks include major patent expirations and uncertainties in the drug pipeline, but oncology and GLP-1 drug commercialization could boost Pfizer's valuation and sustain dividends.
Pfizer's non-COVID commercial portfolio is expanding rapidly, with new product launches and business development driving a 22% growth to nearly $12 billion annually. Meanwhile, Seagen's oncology drugs grew 20% and Biohaven's migraine treatments surge...
The European Commission has authorized Pfizer and BioNTech's updated COVID-19 vaccine for the 2026-2027 season, targeting the XFG variant of the virus. This vaccine is approved for individuals aged 6 months and older and is based on strong clinical a...
Willow Tree Research has started coverage on Pfizer with a contrarian BUY rating and a price target of $32 for the third to fourth quarter of 2026. The firm highlights Pfizer's strong non-COVID drug portfolio, including Padcev and Vyndamax, which are...
